Lyall AE, Pasternak O, Robinson DG, Newell D, Trampush JW, Gallego JA, et al
Novo Nordisk announced that the FDA accepted a new drug application for a 25 mg oral version of semaglutide (Wegovy) for two new indications: Chronic weight management in adults living with obesity or who are overweight with at least one comorbid condition Reduce the risk of major adverse cardiovascular events (MACE) in adults with obesity or overweight with established cardiovascular disease (CVD)
How does Foundayo compare with Wegovy and Zepbound under Bridge
Key Takeaways on GLP-1s for Type 2 Diabetes While GLP-1s are important tools for managing diabetes and promoting weight loss, they are not without risk
Side effects are generally mild, but higher doses may cause diarrhoea, heartburn, stomach pain, vomiting, and headache
One of the most common questions I hear in my orthopedic clinic surrounds the use of peptides